Teacher Retirement System of Texas Sells 2,716 Shares of Lantheus Holdings, Inc. $LNTH

Teacher Retirement System of Texas lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 11.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,736 shares of the medical equipment provider’s stock after selling 2,716 shares during the quarter. Teacher Retirement System of Texas’ holdings in Lantheus were worth $1,779,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cambridge Investment Research Advisors Inc. boosted its holdings in Lantheus by 43.1% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 5,196 shares of the medical equipment provider’s stock worth $507,000 after acquiring an additional 1,564 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Lantheus by 40.2% during the first quarter. Principal Financial Group Inc. now owns 258,495 shares of the medical equipment provider’s stock valued at $25,229,000 after purchasing an additional 74,149 shares in the last quarter. Concurrent Investment Advisors LLC purchased a new position in Lantheus during the first quarter worth about $350,000. Envestnet Asset Management Inc. grew its position in Lantheus by 5.7% in the 1st quarter. Envestnet Asset Management Inc. now owns 124,186 shares of the medical equipment provider’s stock worth $12,121,000 after purchasing an additional 6,659 shares in the last quarter. Finally, Linden Thomas Advisory Services LLC grew its position in Lantheus by 2.9% in the 1st quarter. Linden Thomas Advisory Services LLC now owns 22,569 shares of the medical equipment provider’s stock worth $2,203,000 after purchasing an additional 630 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LNTH has been the topic of a number of research analyst reports. Truist Financial set a $63.00 target price on Lantheus and gave the stock a “hold” rating in a research note on Monday, August 11th. JMP Securities dropped their price target on Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a report on Thursday, August 7th. TD Cowen reduced their price objective on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, September 15th. William Blair reaffirmed a “market perform” rating on shares of Lantheus in a research report on Wednesday, July 16th. Finally, Mizuho cut their price target on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, August 7th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Lantheus currently has an average rating of “Hold” and an average target price of $74.50.

Insider Activity

In related news, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,812,000 shares of company stock valued at $382,427,380 in the last quarter. Corporate insiders own 1.50% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH opened at $56.82 on Tuesday. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07. The stock’s fifty day moving average price is $54.15 and its two-hundred day moving average price is $69.56. The firm has a market cap of $3.86 billion, a PE ratio of 15.11 and a beta of 0.09.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The company had revenue of $92.51 million during the quarter. On average, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.